WARPTECHNEWS · LAB
HomeAIBusinessTechArchive
WARPTECH LAB NEWS

Warptech Lab News aggrega le notizie più rilevanti da oltre 700 fonti internazionali, con classificazione AI, TL;DR sintetici e timeline cluster su singole storie.

Navigazione

  • Home
  • Archivio
  • Editor's Brief
  • Cerca
  • Il tuo account
  • Newsletter tech/AI

Informazioni legali

  • Privacy Policy
  • Termini di servizio
  • Cookie Policy

© 2026 Sparktech S.R.L. — Tutti i diritti riservati. Sito gestito e manutenuto da Sparktech S.R.L.

Sede legale: Corso Libertà 55, 13100 Vercelli (VC), Italia · P.IVA / C.F. 02835910023 · Contatti: admin@warptechlab.com

Home
Storia in 3 fonti

Novo Nordisk shares tumble 18% as CEO warns it will get worse before it gets better

Just as Novo Nordisk showed signs of a recovery, another cold shower hit investors as the drugmaker surprise prereleased its 2026 forecast late Tuesday, sending shares tumbling. 

Raccontata dacnbc.comtheguardian.combbc.com

Confronto fonti

3 prospettive sulla stessa storia
AI · summaries
cnbc.comStai leggendo4 mesi fa

Novo Nordisk shares tumble 18% as CEO warns it will get worse before it gets better

Just as Novo Nordisk showed signs of a recovery, another cold shower hit investors as the drugmaker surprise prereleased its 2026 forecast late Tuesday, sending shares tumbling. 

originale
bbc.com4 mesi fa

Wegovy-maker Novo Nordisk warns of 'painful' price cuts as shares slump

Novo Nordisk is facing "unprecedented" price pressures, "intensifying competition" and patents expiring.

Leggi questa versione → originale
theguardian.com4 mesi fa

Wegovy and Ozempic maker forecasts sharp drop in revenue for 2026

Novo Nordisk share price plunges after blaming lower US drug prices, patent protection issues and rising competition

Leggi questa versione → originale

Timeline cronologica

  1. martedì 3 febbraio 2026·cnbc.com

    Novo Nordisk tumbles 11% after forecasting sales declines this year

    The company is banking on its Wegovy pill and next-generation weight loss injectable CagriSema to recapture share of the key U.S. market. 

  2. mercoledì 4 febbraio 2026·cnbc.com

    Novo Nordisk CEO addresses U.S. headwinds after guidance shock

    Novo Nordisk CEO Mike Doustdar discusses the pharma giant's Q4 reporting, uptake of obesity drugs and how he plans to navigate price pressures throughout 2026.

  3. mercoledì 4 febbraio 2026·cnbc.com

    Novo Nordisk shares tumble 18% as CEO warns it will get worse before it gets better

    Just as Novo Nordisk showed signs of a recovery, another cold shower hit investors as the drugmaker surprise prereleased its 2026 forecast late Tuesday, sending shares tumbling. 

  4. mercoledì 4 febbraio 2026·theguardian.com

    Wegovy and Ozempic maker forecasts sharp drop in revenue for 2026

    Novo Nordisk share price plunges after blaming lower US drug prices, patent protection issues and rising competition

  5. mercoledì 4 febbraio 2026·bbc.com

    Wegovy-maker Novo Nordisk warns of 'painful' price cuts as shares slump

    Novo Nordisk is facing "unprecedented" price pressures, "intensifying competition" and patents expiring.